Two Phase III Trials Show Increase In PFS In Two Distinct Patient Populations
Phase III Trial In Recurrent Disease Shows Lower Risk of Progression or Death by 34%
Two Conflicting Studies Presented at ASCO 2013, FDA Called Upon To Sort Through The Data
Phase III Alimta Trial Fails To Extend Progression-Free Survival Without Grade 4 Adverse Events
Votrient Trial Meets PFS Endpoint In Epithelial Ovarian Cancer
Afinitor Extends PFS In Women With EGFR-2 Positive Disease
Analysis Reveals CAIX Subgroup Responsive to Rencarex Therapy
Inhibitor Reduces Spleen Size By 35 Percent or More in Phase III
CTEP-Approved Trials For the Month of June
FDA Approves Two Oral Drugs For Metastatic Melanoma
Trending Stories
- Rachna Shroff, accomplished GI oncologist and “tireless mentor,” dies at 47
Her endowed award will live on - Is it time to re-assess the practice and practicality of screening colonoscopy?
Modeling data, ACS guideline support greater use of noninvasive tests to ease system strain, help save lives - Kevan Shokat made KRAS druggable. With daraxonrasib now in the clinic, he is “all in” on the ultimate target: p53
Shokat was named 2026 Stephenson Global Prize winner - Iowa’s “cancer crisis” emerges as a top issue on the campaign trail
- California’s Prop 38 is an historic approach to funding medical research, immunology
The $8.4B bond makes a long-term investment in a field with life-saving power - From “default dead” to living the future of cancer care
As founding CEO of GitLab, I went “founder mode” on my osteosarcoma
